Skip to content

Adjuvant Bevacizumab Did Not Improve Invasive Disease-free Survival in Triple-negative Breast Cancer

December 7, 2012
Bookmark and Share

  • Safety profile was consistent with previous trials of bevacizumab.
  • More understanding of triple-negative breast cancer is still needed.
  • Final overall survival data are expected in 2013.

SAN ANTONIO — Patients who received one year of bevacizumab in addition to chemotherapy for the postsurgical treatment of triple-negative breast cancer had no statistically significant improvement in invasive disease-free survival compared with patients treated with chemotherapy alone, according to the primary results of the phase III BEATRICE study.

“This study did not confirm the hypothesis that adding bevacizumab to chemotherapy would improve patients’ outcomes,” said David Cameron, M.D., professor of oncology at Edinburgh University in Scotland, who presented the results at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 4-8. “Therefore, sadly for patients, we have nothing extra to add to chemotherapy for early, triple-negative breast cancer.”

Prior research has shown that bevacizumab combined with chemotherapy significantly improves progression-free survival in metastatic breast cancer and improves pathologic complete response in the neoadjuvant setting. The dependence of micrometastases on angiogenesis suggested to Cameron and his colleagues that patients might benefit from anti-angiogenic strategies, such as bevacizumab, applied in the adjuvant setting.

In BEATRICE, an open-label, multinational, phase III study, researchers randomly assigned 2,591 patients with triple-negative operable primary invasive breast cancer to four or more cycles of anthracycline-based or taxane-based chemotherapy with or without one year of bevacizumab.

At a median follow-up of 32 months, the hazard ratio for invasive disease-free survival was 0.87 (95% CI 0.72–1.07) in favor of patients assigned to chemotherapy and bevacizumab. Researchers reported 107 deaths among patients who received chemotherapy alone compared with 93 deaths among those who received chemotherapy and bevacizumab.

“The findings are reminiscent of what was reported in operable colorectal cancer,” Cameron said. “Bevacizumab clearly does something in this setting, but the effect is not sustained, and therefore, adding bevacizumab to chemotherapy for all these patients is not the way to improve their chances.”

Researchers found no difference in the amount of chemotherapy delivered and found no increase in the risk for fatal adverse events in patients assigned to bevacizumab. However, the addition of bevacizumab to chemotherapy was associated with an increase in grade 3 or worse hypertension, left ventricular dysfunction and congestive heart failure.

“We still need to understand what is special about the biology of breast cancers that do not express hormone receptors, nor overexpress HER2,” Cameron said. “We need to explore which cancers might benefit from other additional therapies, including the possibility that some of them might benefit from drugs like bevacizumab.”

# # #

The mission of the 2012 CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor and the AACR’s scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. For more information about the symposium, please visit

Media Contact:
Jeremy Moore
(215) 446-7109
In San Antonio, Dec. 4-8:
(210) 582-7035

No comments yet

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: